Closely-held Jeeva Informatics has developed a centralized electronic clinical platform that aims to help clinical trial sponsors increase the efficiency of their clinical trials, while expanding trial access to...
Closely-held EndoGlow, a medical device company, is revolutionizing minimally invasive surgery and improving patient outcomes by enhancing visualization through its proprietary Tissue Reveal Technology (TRT), a polymer...
Closely-held Inbound Health is enabling its health system partners to provide hospital and skilled nursing facility (SNF)-level care to patients in the comfort of their own home.
Korro Bio’s reverse merger with Frequency Therapeutics (NASDAQ:FREQ), which is expected to close in the 2023 fourth quarter, and concurrent financing are expected to build up an investor base to bankroll Korro’s...
MIRA Pharmaceuticals (NASDAQ:MIRA) is developing MIRA1a, a novel synthetic analog of THC (tetrahydrocannabinol) to treat anxiety and cognitive decline in the elderly and neuropathic pain, with a lower impurity profile...
Avenue Therapeutics (NASDAQ:ATXI) has taken a quantum leap into the CNS space during landscape over the past 12 months by adding two early-stage clinical assets to its pipeline to complement its late-stage intravenous...
Closely-held Glyscend Therapeutics is developing an orally administered, gut-restricted drug for Type 2 diabetes and obesity, based on “duodenal exclusion” physiology, a key mechanism of gastric bypass surgery.
Closely-held Convergent Therapeutics is rapidly advancing a next generation alpha-emitting prostate-specific membrane antigen (PSMA)-targeted radioantibody for an IND filing in October.
Closely-held Halia Therapeutics is developing a broad pipeline of novel therapies that are essential mediators of immune cell signaling with the potential to improve the lives of patients with inflammatory disorders and...
Immuneering (NASDAQ:IMRX) is integrating translational medicine with bioinformatics to discover and develop novel product candidates for a broad population of cancer patients with RAS mutations, an approach the company...